How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,635 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

13801. The signaling adapter protein PINCH is up-regulated in the stroma of common cancers, notably at invasive edges. (Abstract)

polyclonal antibody was raised to a purified 6-histidine PINCH fusion protein and used to evaluate 74 cases comprising 33 breast carcinomas (21 ductal carcinomas, 6 lobular carcinomas, 4 ductal carcinomas in situ, 2 lobular carcinomas in situ), 22 prostate carcinomas, 5 colon carcinomas, 6 lung carcinomas (3 adenocarcinomas and 3 squamous carcinomas), and 8 skin carcinomas (4 basal cell carcinomas and 4 squamous cell carcinomas) by immunoperoxidase histochemistry of formalin-fixed, paraffin-embedded (...) tissues. Lysates of frozen tissue from the epithelium of two normal breasts and six breast carcinomas were evaluated by immunoblotting.Immunostaining for PINCH was increased in the cytoplasm of fibroblastoid cells in areas of the tumor-associated stroma in all carcinomatous tissues evaluated. The most intense stromal immunostaining for PINCH was noted at invasive edges, particularly in breast carcinomatous tissue. Immunoblotting of lysates from normal breast and breast carcinomatous tissue confirmed

2002 Cancer

13802. Primary and metastatic cancer of the parotid: comparison of clinical behavior in 232 cases. (Abstract)

cancer, 24 patients with squamous cell carcinoma, 16 with melanoma, and 2 with other metastatic malignancies. Conservative parotidectomy, preserving the main trunk of the facial nerve, was performed in 185 patients, and 47 patients had a radical parotidectomy sacrificing the facial nerve. There were 54 therapeutic and 110 elective neck dissections. Adjuvant radiotherapy was given to 39 patients with primary cancer, 86 with squamous cell carcinoma, 50 with melanoma, and 8 in the other metastatic group (...) prospectively documented series of 232 parotidectomies carried out for treatment of cancer from 1988 to 1999 was reviewed. There were 177 male and 55 female patients with a median age of 65 years (age range, 17-97 y). Median follow-up time was 4 years. Pathological groups included 54 patients with primary parotid cancer, 101 with metastatic cutaneous squamous cell carcinoma, 69 with metastatic melanoma, and 8 with other metastatic cancers.Neck nodes were clinically positive in 12 patients with primary

2003 Laryngoscope

13803. Adjuvant levamisole in the treatment of patients with resectable lung cancer. (Abstract)

use Adult Aged Carcinoma, Squamous Cell drug therapy Chemical Phenomena Chemistry Clinical Trials as Topic Double-Blind Method Female Follow-Up Studies Humans Hypersensitivity, Delayed immunology Levamisole administration & dosage therapeutic use Lung Neoplasms drug therapy immunology surgery Male Middle Aged Prognosis Random Allocation Risk Skin Tests Smoking 197 1980 1 1 1980 1 1 0 1 1980 1 1 0 0 ppublish 6999969 (...) Adjuvant levamisole in the treatment of patients with resectable lung cancer. 6999969 1980 12 18 2013 11 21 0003-4762 12 Suppl 27 1980 Annals of clinical research Ann. Clin. Res. Adjuvant levamisole in the treatment of patients with resectable lung cancer. 1-83 Amery W K WK eng Clinical Trial Journal Article Randomized Controlled Trial Review Finland Ann Clin Res 0220042 0003-4762 0 Adjuvants, Immunologic 2880D3468G Levamisole IM Adenocarcinoma drug therapy Adjuvants, Immunologic therapeutic

1980 Annals Of Clinical Research Controlled trial quality: uncertain

13804. Epidermolysis bullosa and cancer. (Abstract)

Epidermolysis bullosa and cancer. Epidermolysis bullosa (EB) encompasses a group of inherited blistering skin disorders classified into three main subtypes of simplex, junctional and dystrophic. In recent years there have been substantial advances in our understanding of the molecular basis of these conditions and in the management of such patients. In spite of this progress, squamous cell carcinoma (SCC) is still a major cause of morbidity and mortality, particularly in Hallopeau--Siemens (...) recessive dystrophic EB. The reason why dystrophic EB patients readily develop SCC with such a poor prognosis remains a mystery. This article reviews the epidemiology of cancer in inherited EB and also discusses the clinical features, histological assessment and treatment options of SCC in EB.

2002 Clinical & Experimental Dermatology

13805. Imiquimod to treat different cancers of the epidermis. (Abstract)

Imiquimod to treat different cancers of the epidermis. Topical immunomodulatory therapy with imiquimod has been recently used for the treatment of actinic keratoses, intraepithelial carcinoma, and small basal cell carcinoma (BCC) besides the licensed indication of extragenital warts (condyloma).We treated several patients with particular epidermal neoplasias such as squamous cell cancer (SCC) and basal cell cancer of sclerodermiform type three times per week for 4 to 12 weeks.We report several (...) novel aspects of the treatment of epidermal cancers with self-applied, nonpainful, immunomodulatory therapy. First, we treated-for the first time-two immunosuppressed renal transplant patients for invasive SCC with imiquimod. Interestingly, systemic immunosuppression did not adversely affect the response to therapy. Second, one patient with the high-risk and aggressive growth pattern of basal cell cancer (sclerodermiform histology) was cured from his disease at a particular location in the face

2003 Dermatologic Surgery

13806. Photodynamic Therapy for 101 Early Cancers of the Upper Aerodigestive Tract, the Esophagus, and the Bronchi: A Single-Institution Experience Full Text available with Trip Pro

carcinomas in the upper aerodigestive tract, the esophagus, and the tracheobronchial tree. Sixty-four patients with 101 squamous cell carcinomas were treated with three different photosensitizers: hematoporphyrin derivative (HPD), Photofrin II, and tetra (m-hydroxyphenyl)chlorin (mTHPC). Seventy-seven (76%) tumors showed a complete rsponse with no recurrence after a mean follow-up period of 27 months. There was no significant difference in terms of cure rates among the three dyes. However, mTHPC has (...) Photodynamic Therapy for 101 Early Cancers of the Upper Aerodigestive Tract, the Esophagus, and the Bronchi: A Single-Institution Experience Cancer, when detected at an early stage, has a very good probability of being eradicated by surgery or radiotherapy. However, less aggressive treatments also tend to provide high rates of cure without the side effects of radical therapy. We report on the results of our clinical experience with photodynamic therapy (PDT) for the treatment of early

1999 Diagnostic and therapeutic endoscopy

13807. Radiation Therapy With or Without Bicalutamide and Goserelin in Treating Patients With Prostate Cancer

cancer except localized basal cell or squamous cell skin cancer unless disease free for at least 5 years No major medical or psychiatric illness that would preclude study completion, compliance, or follow-up PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy No prior chemotherapy for prostate cancer Endocrine therapy No prior androgen-deprivation therapy Radiotherapy No prior pelvic radiotherapy No prior prostate brachytherapy Surgery No prior bilateral orchiectomy No prior radical (...) , 2015 Last Verified: December 2015 Keywords provided by Memorial Sloan Kettering Cancer Center: adenocarcinoma of the prostate stage III prostate cancer Additional relevant MeSH terms: Layout table for MeSH terms Prostatic Neoplasms Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Neoplasms Genital Diseases, Male Prostatic Diseases Androgens Goserelin Bicalutamide Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Antineoplastic Agents

2003 Clinical Trials

13808. Radiation Therapy, Mitomycin, and Either Fluorouracil or Cisplatin in Treating Patients With Locally Advanced Anal Cancer

Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed squamous cell anal carcinoma Keratinizing or non-keratinizing The following stages are eligible: T2, N0, M0 with maximum tumor diameter at least 4 cm T3-T4, N0, M0 Any T, N1-N3, M0 Tumor located in the anal canal OR in the anal margin and infiltrating the anal canal No primary adenocarcinoma of the anus Measurable disease (...) of Cancer - EORTC: squamous cell carcinoma of the anus stage II anal cancer stage IIIA anal cancer stage IIIB anal cancer Additional relevant MeSH terms: Layout table for MeSH terms Anus Neoplasms Rectal Neoplasms Colorectal Neoplasms Intestinal Neoplasms Gastrointestinal Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Anus Diseases Rectal Diseases Cisplatin Fluorouracil Mitomycins Mitomycin Antineoplastic Agents

2003 Clinical Trials

13809. S0230 Goserelin in Preventing Ovarian Failure in Women Receiving Chemotherapy for Breast Cancer

Hepatic Not specified Renal Not specified Other Not pregnant or nursing Fertile patients must use effective barrier contraception No other prior malignancy except adequately treated basal cell or squamous cell skin cancer or any in situ cancer from which the patient has been disease-free for at least 5 years after treatment with curative intent PRIOR CONCURRENT THERAPY: Biologic therapy Not specified Chemotherapy See Disease Characteristics No prior cytotoxic chemotherapy Endocrine therapy No other (...) information Ages Eligible for Study: 18 Years to 49 Years (Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed invasive breast cancer Stage I-IIIA Operable disease Bilateral synchronous invasive breast cancer allowed provided primary tumors were diagnosed no more than 1 month apart and both tumors are hormone receptor negative Must be planning to receive 3-8 months of a preoperative or postoperative chemotherapy regimen

2003 Clinical Trials

13810. Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer

ways to stop tumor cells from dividing so they stop growing or die. Combining cisplatin with gemcitabine may make the tumor cells more sensitive to radiation therapy and may kill more tumor cells. Condition or disease Intervention/treatment Phase Cervical Adenocarcinoma Cervical Adenosquamous Carcinoma Cervical Small Cell Carcinoma Cervical Squamous Cell Carcinoma Stage IB Cervical Cancer Stage IIA Cervical Cancer Stage IIB Cervical Cancer Stage III Cervical Cancer Stage IVA Cervical Cancer Drug (...) Update Posted: December 25, 2014 Last Verified: December 2014 Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Adenocarcinoma Uterine Cervical Neoplasms Carcinoma, Small Cell Small Cell Lung Carcinoma Carcinoma, Adenosquamous Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Uterine Cervical Diseases Uterine Diseases Genital

2003 Clinical Trials

13811. Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Cancer of the Vulva

use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving chemotherapy with radiation therapy before surgery may shrink the tumor so it can be removed during surgery. Condition or disease Intervention/treatment Phase Stage III Vulvar Cancer Stage IVB Vulvar Cancer Vulvar Squamous Cell Carcinoma Radiation: 3-Dimensional Conformal Radiation Therapy Drug: Cisplatin Procedure: Conventional Surgery Phase 2 (...) 2011 Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Vulvar Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Vulvar Diseases Genital Diseases, Female Cisplatin Antineoplastic Agents

2003 Clinical Trials

13812. Salivary Gland Surgery Before Radiation Therapy in Preventing Radiation-Caused Xerostomia in Patients With Head and Neck Cancer

: No Criteria DISEASE CHARACTERISTICS: One of the following diagnoses: Histologically confirmed, previously untreated squamous cell carcinoma of the oropharynx, hypopharynx, or larynx Head and neck cancer of unknown primary with unilateral metastases to the neck nodes No N3 disease No carcinoma of the oral cavity or nasopharynx No bilateral neck node involvement No suspicious neck node on the contralateral neck or the side chosen for salivary gland transfer by CT scan or MRI No pre-epiglottic space (...) IV squamous cell carcinoma of the hypopharynx stage IV squamous cell carcinoma of the oropharynx Additional relevant MeSH terms: Layout table for MeSH terms Head and Neck Neoplasms Xerostomia Radiation Injuries Neoplasms by Site Neoplasms Salivary Gland Diseases Mouth Diseases Stomatognathic Diseases Wounds and Injuries

2003 Clinical Trials

13813. Triptorelin With Either Exemestane or Tamoxifen in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

effective nonhormonal contraception No history of noncompliance to medical regimens No other nonmalignant systemic disease that would preclude prolonged follow-up No other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, nonbreast carcinoma in situ, contralateral or ipsilateral carcinoma in situ of the breast, or other nonrecurrent invasive nonbreast malignancy, including any of the following: Stage I papillary thyroid cancer Stage IA carcinoma (...) -regional axillary disease Prior surgery for primary breast cancer of 1 of the following types: Total mastectomy with or without adjuvant radiotherapy Breast-conserving procedure (e.g., lumpectomy, quadrantectomy, or partial mastectomy with margins negative* for invasive disease and ductal carcinoma in situ) with planned radiotherapy NOTE: *If all other margins are clear a positive posterior (deep) margin is permitted, provided the excision was performed down to the pectoral fascia and all tumor has

2003 Clinical Trials

13814. Suppression of Ovarian Function Plus Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer

ipsilateral or contralateral invasive breast cancer; patients with synchronous bilateral invasive breast cancer (diagnosed histologically within 2 months) are eligible if the bilateral disease meets all other eligibility criteria Patients with previous or concomitant invasive malignancy are not eligible; the exceptions are patients with the following (and only the following) malignancies (previous or concomitant) who are eligible if adequately treated: Basal or squamous cell carcinoma of the skin In situ (...) tamoxifen alone in preventing the recurrence of hormone-responsive breast cancer. PURPOSE: This randomized phase III trial studies ovarian suppression with either tamoxifen or exemestane to see how well they work compared to tamoxifen alone in treating premenopausal women who have undergone surgery for hormone-responsive breast cancer. Condition or disease Intervention/treatment Phase Estrogen Receptor Positive Breast Cancer Progesterone Receptor Positive Tumor Recurrent Breast Carcinoma Stage IA Breast

2003 Clinical Trials

13815. Suppression of Ovarian Function and Either Tamoxifen or Exemestane With or Without Chemotherapy in Treating Premenopausal Women With Resected Breast Cancer

prior or concurrent invasive malignancy except adequately treated basal cell or squamous cell skin cancer, nonbreast carcinoma in situ without invasion, contralateral or ipsilateral carcinoma in situ of the breast No prior or concurrent nonbreast invasive malignancy within the past 5 years that is nonrecurrent including any of the following: Stage I papillary thyroid cancer Stage Ia carcinoma of the cervix Stage Ia or b endometrioid endometrial cancer Borderline or stage I ovarian cancer No other (...) ., lumpectomy, quadrantectomy, or partial mastectomy with margins clear* of invasive cancer and ductal carcinoma in situ) followed by radiotherapy NOTE: *If all other margins are clear, a positive posterior (deep) margin is permitted, provided the excision was performed down to the pectoral fascia and all tumor has been removed OR a positive anterior (superficial; abutting skin) margin is allowed provided all tumor was removed Prior axillary lymph node dissection or negative axillary sentinel node biopsy

2003 Clinical Trials

13816. Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer

bone scan or measurable disease). Progressive disease after androgen deprivation. No prior chemotherapy or immunotherapy (tumor vaccine, cytokine, or growth factor given to control prostate cancer). Exclusion Criteria: Other prior malignancy, except for adequately treated basal or squamous cell skin cancer or superficial bladder cancer, or any other cancer from which the patient has been disease-free for greater than or equal to 5 years. Previous occurrence of autoimmune disease. Active infection (...) (docetaxel) in combination with MDX-010 Condition or disease Intervention/treatment Phase Prostate Cancer Drug: MDX-010 / MDX-010 + Docetaxel Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Allocation: Randomized Intervention Model: Crossover Assignment Masking: None (Open Label) Primary Purpose: Treatment Official Title: A Randomized Study Comparing 4 Monthly Doses of MDX-010 (CTLA-4) as a Single Agent or Used in Combination With a Single Dose

2002 Clinical Trials

13817. S0030: Capecitabine in Treating Older Patients W/Metastatic or Recurrent Colorectal Cancer That Cannot Be Surgically Removed

than 2 times ULN Creatinine clearance greater than 50 mL/min Other Not pregnant or nursing Fertile patients must use effective contraception HIV negative No known seizure disorder No other malignancy except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, adequately treated stage I or II cancer currently in complete remission, or any other cancer for which the patient has been disease free for 5 years PRIOR CONCURRENT THERAPY: Biologic therapy (...) : Completed First Posted : January 27, 2003 Last Update Posted : January 3, 2013 Sponsor: Southwest Oncology Group Collaborator: National Cancer Institute (NCI) Information provided by (Responsible Party): Southwest Oncology Group Study Details Study Description Go to Brief Summary: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of capecitabine in treating older patients who have

2002 Clinical Trials

13818. Erlotinib, Docetaxel, and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer

may make the tumor cells more sensitive to radiation therapy and may kill more tumor cells. Phase I trial to study the maximum tolerated dose (MTD) of combining erlotinib with docetaxel and radiation therapy in treating patients who have locally advanced head and neck cancer Condition or disease Intervention/treatment Phase Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma Stage III Squamous Cell Carcinoma of the Hypopharynx Stage III Squamous Cell Carcinoma of the Larynx (...) is treated on this protocol HIV positive patients are excluded from participation Patients with history of any other malignancy (except squamous cell or basal cell cancer of the skin or CIS of cervix) are ineligible unless a period of 5 years has elapsed since treatment of the previous cancer and the patient has remained continuously disease free Patients who are felt to be poorly compliant Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you

2002 Clinical Trials

13819. Imatinib Mesylate in Treating Patients With Stage III or Stage IV Ovarian Epithelial or Primary Peritoneal Cancer

within the past 5 years except adequately treated basal cell or squamous cell skin cancer, carcinoma in situ of the cervix, or other adequately treated stage I or II cancer in complete remission At least 28 days since prior biologic therapy No concurrent anticancer biologic therapy No concurrent cytokines (e.g., filgrastim [G-CSF] or sargramostim [GM-CSF]) At least 28 days since prior chemotherapy No more than 3 prior chemotherapy regimens in addition to frontline chemotherapy Retreatment (...) Last Update Posted : January 24, 2013 Sponsor: National Cancer Institute (NCI) Information provided by (Responsible Party): National Cancer Institute (NCI) Study Details Study Description Go to Brief Summary: Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have stage III or stage IV ovarian epithelial or primary peritoneal cancer that has not responded to previous treatment. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes

2002 Clinical Trials

13820. Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer

stage IIA cervical cancer cervical squamous cell carcinoma cervical adenocarcinoma cervical adenosquamous cell carcinoma Additional relevant MeSH terms: Layout table for MeSH terms Uterine Cervical Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Cervical Diseases Uterine Diseases Genital Diseases, Female Cisplatin Antineoplastic Agents (...) below. For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria DISEASE CHARACTERISTICS: Histologically confirmed cervical cancer, including the following subtypes: Squamous cell carcinoma Adenosquamous cell carcinoma Adenocarcinoma (excluding small cell, clear cell, and other rare variants of the classical adenocarcinoma) FIGO stage IB2, IIA (greater

2002 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>